APA (7th ed.) Citation

AR, O., CA, L., JA, H., AG, R., & MS, S. (2012). The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes. The Journal of pharmacology and experimental therapeutics, 342(1), 23. https://doi.org/10.1124/jpet.112.192187

Chicago Style (17th ed.) Citation

AR, Ochman, Lipinski CA, Handler JA, Reaume AG, and Saporito MS. "The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator That Elicits a Rapid-onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes." The Journal of Pharmacology and Experimental Therapeutics 342, no. 1 (2012): 23. https://doi.org/10.1124/jpet.112.192187.

MLA (9th ed.) Citation

AR, Ochman, et al. "The Lyn Kinase Activator MLR-1023 Is a Novel Insulin Receptor Potentiator That Elicits a Rapid-onset and Durable Improvement in Glucose Homeostasis in Animal Models of Type 2 Diabetes." The Journal of Pharmacology and Experimental Therapeutics, vol. 342, no. 1, 2012, p. 23, https://doi.org/10.1124/jpet.112.192187.